Can Fite Biofarma Ltd has a consensus price target of $11.5, established from looking at the 4 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on October 24, 2023, June 2, 2023, and March 13, 2023. With an average price target of $28.67 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 1449.55% upside for Can Fite Biofarma Ltd from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
10/24/2023 | CANF | Buy Now | Can Fite Biofarma | $1.85 | 872.97% | HC Wainwright & Co. | Vernon Bernardino | $34 → $18 | Maintains | Buy | Get Alert |
06/02/2023 | CANF | Buy Now | Can Fite Biofarma | $1.85 | 1737.84% | HC Wainwright & Co. | Vernon Bernardino | → $34 | Reiterates | → Buy | Get Alert |
03/13/2023 | CANF | Buy Now | Can Fite Biofarma | $1.85 | 1737.84% | HC Wainwright & Co. | Vernon Bernardino | → $34 | Reiterates | → Buy | Get Alert |
06/24/2021 | CANF | Buy Now | Can Fite Biofarma | $1.85 | 170.27% | Aegis Capital | Chrishan Anketell | — | Initiates | → Buy | Get Alert |
The latest price target for Can Fite Biofarma (AMEX: CANF) was reported by HC Wainwright & Co. on October 24, 2023. The analyst firm set a price target for $18.00 expecting CANF to rise to within 12 months (a possible 809.09% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Can Fite Biofarma (AMEX: CANF) was provided by HC Wainwright & Co., and Can Fite Biofarma maintained their buy rating.
There is no last upgrade for Can Fite Biofarma.
There is no last downgrade for Can Fite Biofarma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Can Fite Biofarma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Can Fite Biofarma was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
While ratings are subjective and will change, the latest Can Fite Biofarma (CANF) rating was a maintained with a price target of $34.00 to $18.00. The current price Can Fite Biofarma (CANF) is trading at is $1.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.